Drug intelligence / Profile preview

PEV7C9

Development stage: Unknown
Lead developer: Pevion Biotech
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intravaginal

Overview

PEV7C9 is a virosomal vaccine candidate that has been studied for intravaginal administration. It was evaluated in a clinical trial to assess its safety and immunogenicity, with placebo as the comparator. The specific antigenic target, mechanism of action, and developer details are not provided in the available sources. The virosomal platform generally involves using virus-like particles to deliver antigens and stimulate an immune response.

Beyond the preview

Go deeper on PEV7C9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEV7C9.

Explore the full profile